Not available for public use according to Lilly.
Open related pageAvailability
retatrutide availability
As of May 3, 2026, Lilly says retatrutide is not available for public use. Launch depends on trial completion and regulatory review.
Direct answer
Retatrutide availability is trial-only in official Lilly language. It is not FDA approved and should not be treated as a normal prescription, pharmacy, or online retail product.
ClinicalTrials.gov lists public study records and recruiting status.
Open related pageCountry-specific seller pages are not regulatory approval evidence.
Open related pageWhat to know before acting on this search
- Lilly says retatrutide is in Phase 3 clinical trials and additional results are expected as the program continues.
- A country name such as UK, Colombia, Australia, or Canada in a search result does not prove legal availability.
- Online price or stock claims are marketplace claims, not official access pathways.
- Approved alternatives may be available through regulated prescription channels depending on country, indication, and eligibility.
Safety and compliance notes
- Do not rely on source pages that claim retatrutide is in stock, pharmacy-grade, compounded, or prescription-free.
- Imported or research-use products may create legal, sterility, quality, and dosing risks.
- Availability should be verified through regulators, official company statements, or clinical trial teams.
Safer next step
Use the country availability guide and clinical trial finder, then discuss approved-care options with a healthcare professional.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. FDA-approved medicines such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.